

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: **84113923.1**

(51) Int. Cl.⁴: **C 08 B 37/16**

(22) Date of filing: **17.11.84**

(30) Priority: **22.02.84 IT 1973584**

(43) Date of publication of application:
11.09.85 Bulletin 85/37

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: **CHIESI FARMACEUTICI S.p.A.**
Via Palermo, 26/A
I-43100 Parma(IT)

(72) Inventor: **Chiesi, Paolo**
Via Palermo, 26/A
Parma(IT)

(72) Inventor: **Servadio, Vittorino**
Via Palermo, 26/A
Parma(IT)

(74) Representative: **Bianchetti, Giuseppe**
Studio Consulenza Brevettuale Via Senato 24
I-20121 Milan(IT)

(54) New compounds having antiinflammatory activity, obtained by complexation with beta-cyclodextrin, and pharmaceutical compositions containing them.

(57) New inclusion compounds of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide with α , β or γ cyclodextrins, obtained by reaction of said cyclodextrins and said 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide in aqueous or water/organic solutions are described. The ratio between 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-1,1-dioxide and the cyclodextrins is comprised between 1:10 and 1:1; preferably, it is about 1:2.5.

The compounds of the invention possess high antiinflammatory and analgesic activities, together with a considerably reduced gastrolesive action.

EP 0 153 998 A2

New compounds having antiinflammatory activity,
obtained by complexation with β -cyclodextrin,
and pharmaceutical compositions containing them

The present invention refers to new compounds obtained by complexation of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (hereinafter referred to as piroxicam) with
5 α -, β - or γ -type cyclodextrins.

Piroxicam is a compound belonging to the class of the Non Steroidal AntiInflammatory drugs (NSAI) which, thanks to its remarkable analgesic and antiphlogistic activity, is effectively employed
10 in the treatment of arthro-rheumatic diseases. On the other hand, piroxicam is responsible of lesive effects on the gastrointestinal mucosa, though at a lower extent with respect to other drugs of the same therapeutical class widely em-
15 ployed in the clinical praxis.

In addition, piroxicam is practically insoluble in water, and this may represent a limiting factor for an optimal employment of the substance.

It has now been found, and this is the object
20 of the present invention, that piroxicam can advantageously be complexed by inclusion into α -, β - or γ -type cyclodextrins.

The cyclodextrins are natural cyclic compounds consisting of 6(α), 7(β) or 8(γ) (1 \rightarrow 4) D-glu-
25 copyranosidic units.

The so obtained complex possesses a high solu-

- 2 -

bility, is rapidly absorbed and is better tolerated. In this complex, piroxicam and the cyclodextrins may be present in ratios comprised between 1:1 and 1:10, preferably 1:2.5.

5 The preparation of the compound can be carried out in different ways:

- a) piroxicam is directly dissolved in an aqueous solution of the selected cyclodextrin, from which the complex separates by crystallization;
- 10 b) piroxicam is dissolved in an organic medium, the organic solution is mixed under stirring with an aqueous solution of the selected cyclodextrin, and the obtained complex is finally separated by crystallization;
- 15 c) the compounds are dissolved under stirring in a water/ammonia solution, and the complex is subsequently separated by drying up;
- 20 d) the compounds are dissolved under stirring in a hot water/ammonia solution, and the complex is subsequently separated by freeze-drying or atomization in air stream.

The compound obtained by this last procedure seems to display more favorable biological properties.

25 The following examples are only given with the purpose of better illustrating the invention, but in no way they must be construed as a limitation of the scopes of the invention itself.

EXAMPLE 1

30 50 Milligrams (0.15 mmoles) of piroxicam and 426

- 3 -

mg (0.375 mmoles) of β -cyclodextrin were dissolved in 100 ml of water at 60°C. After stirring for three hours at room temperature and cooling to 3°C, the product separated by crystallization.

5 EXAMPLE 2

3 Grams (2.643 mmoles) of β -cyclodextrin were dissolved in 100 ml of water, by applying a gentle heating, and the resulting solution was added with a solution of 352.11 mg (1.06 mmoles) of piroxicam in
10 50 ml of an organic, water immixable solvent, e.g. ethyl acetate. After shaking for 12 hours at room temperature and cooling to 3°C, again under shaking, a precipitate was collected, washed with ethyl acetate and dried in vacuo at 40°C.

15 EXAMPLE 3

1.3 Grams (3.92 mmoles) of piroxicam and 11.18 g (9.85 mmoles) of β -cyclodextrin were poured under stirring into 780 ml of water. The resulting solution was subsequently added with 26 ml of aqueous
20 30% ammonium hydroxide and the whole was stirred for 3 hours at room temperature. After 48 hours, the solution was evaporated to dryness and the obtained product was further dried under vacuum in oven at 40°C.

25 EXAMPLE 4

250 Grams (0.220 moles) of β -cyclodextrin were suspended in 1500 ml of water, the suspension was brought to 60°C under stirring and subsequently added with 29.20 g (0.088 moles) of piroxicam and 50
30 ml of aqueous 30% ammonium hydroxide. The limpid

- 4 -

solution was then poured into a freeze-dryer, pre-cooled to -20°C . After freeze-drying, the product was refined.

EXAMPLE 5

5 250 Grams (0.220 moles) of β -cyclodextrin were suspended in 1500 ml of water, the suspension was brought to 60°C under stirring and subsequently added with 29.2 g (0.088 moles) of piroxicam and 50 ml of aqueous 30% ammonium hydroxide. The limpid so-
10 lution was then dried by atomization in air stream, pH = 5.7 (determined on a saturated solution of piroxicam/ β -cyclodextrin).

The so obtained product was characterized as follows:

15 a) Quantitative determination of piroxicam complexed by the β -cyclodextrin
An amount of complex corresponding to about 10 mg of piroxicam, accurately weighed, was taken up with 1000 ml of 0.1N NaOH in methanol. The amount
20 of piroxicam in the complex was spectrophotometrically determined on the solution, previously filtered through paper, at 358 nm against 0.1N NaOH in methanol.

b) Characterization of the complex by Differential Scanning Calorimetry (D.S.C.)

25 About 5 mg of the complex piroxicam/ β -cyclodextrin, exactly weighed, were analyzed under the following conditions:

starting temperature	70°C
temperature gradient	$10^{\circ}\text{C}/\text{min.}$
30 final temperature	350°C

- 5 -

The typical endothermic peaks of free piroxicam, appearing at about 200°C, must be absent. The results are shown in Figure 1, in which the D.S.C.-curve of the complex piroxicam/ β -cyclodextrin (Drawing A) is compared with that of a physical mixture of piroxicam and β -cyclodextrin (Drawing B).

The solubility characteristics of the complex piroxicam/ β -cyclodextrin (1:2.5), obtained by the freeze-drying method, were determined with the aid of a "Dissolution Tester" apparatus, in agreement with the specification of the U.S. Pharmacopoeia, 20th. edition, at a speed of 100 r.p.m. and at the temperature of 25°C.

EXAMPLE 6

7.5 Grams of piroxicam/ β -cyclodextrin were poured into 150 ml of water at 25°C under stirring. At predetermined time intervals, samples of 5 ml of suspension were collected and filtered through 0.2 μ . 2 Milliliters of the filtrate were diluted to 500 with 0.1N NaOH in methanol immediately after the filtration. The whole was again filtered through paper.

The amount of piroxicam in the solution was spectrophotometrically determined at 358 nm against a solution of 0.1N NaOH in methanol.

After 30 minutes since the beginning of the dissolution test, the per cent concentration of piroxicam complexed with β -cyclodextrin was 0.0463 (expressed as g/100 ml) whereas, under the same experimental conditions and at the same time, the

- 6 -

per cent concentration of piroxicam alone was 0.0111 (expressed as g/100 ml).

Accordingly, the solubility of piroxicam in the complex with β -cyclodextrin is 4 times higher than that of piroxicam as such.

The complex piroxicam/ β -cyclodextrin 1:2.5 obtained by the freeze-drying procedure was investigated with respect to its pharmaco-toxicological properties in comparison with piroxicam as such.

10 All the indicated dosages are expressed as dosages of active principle (piroxicam).

Antiinflammatory activity

The antiinflammatory activity was determined by means of the carrageenin induced oedema test, according to the methodology reported by C.A. Winter et al in Proc. Soc. Exptl. Biol. Med. 111, 544, 1962. As the test animals, male Crl:CD(SD) rats, weighing 150-170 g, were employed. The animals were housed under standard conditions and fastened for 18 hours before the beginning of the experiment. Water was available ad libitum.

The activity of the compounds to be tested, administered at different dosages by oral route, was determined by measuring the inhibition of the oedema induced in the rat paw by the injection of 0.1 ml of a 1% carrageenin suspension in physiological solution into the subplantar aponeurosis of the right hind paw.

The obtained results were expressed both as ED₅₀ values, determined in correspondence of the acti-

- 7 -

vity peak on the regression line log. of the dosage-% inhibition of the oedema, and as ED_{30} values, calculated on the regression lines log. of the dosage-% inhibition of the oedema over the controls, determined as the mean value of AUC (area under Curve representing the development of the paw volume in the time).

In addition, it was determined the kinetic of the activity of the two formulations under investigation, by calculating the ED_{30} values at 2, 3, 4 and 6 hours since the carrageenin injection.

The results are reported in Tables 1 and 2.

TABLE 1 - Antiinflammatory activity determined by the carrageenin induced oedema test in rats. Comparison between the complex piroxicam/ β -cyclodextrin and piroxicam.

Compound	Peak Activity ED_{50} (mg/kg)	PR	Activity on AUC ED_{30} (mg/kg)	PR
Complex piroxicam/ β -cyclodextrin	1.1	2.1	1.2	2.1
Piroxicam	2.3	1	2.5	1

P.R. = Potency ratio over piroxicam (Piroxicam = 1)




TABLE 2 - Antiinflammatory activity determined by the carrageenin induced oedema test in rats. Kinetic of the activity of the compounds, expressed as ED_{30} , at different time intervals since the carrageenin injection

Compound	ED_{30} (mg/kg) at different time intervals			
	2 h	3 h	4 h	6 h
Complex piroxicam/ β -cyclodextrin	0.38	0.76	1.5	11.9
Piroxicam	0.60	1.6	3.1	9.7
Potency ratio (piroxicam = 1)	1.6	2.1	2.1	0.82

Gastrolesive Action

The gastrolesive action was tested on rats fastened for 18 hours, through macroscopical examination of the gastric mucosa, 5 hours after the administration of the substances under investigation. For each treatment, the regression lines log. of the dosage-mm of ulceration (single values for each animal) were determined. These lines allowed to calculate, for each compound, the UD_0 values i.e., the maximum dosages at which no lesions are observed.

Finally, it was also determined the therapeutic index of the new compound piroxicam/ β -cyclodextrin, in comparison with piroxicam. Said index was expressed as the ratio UD_0/ED_{30} wherein UD_0 and ED_{30} are as above defined.

The obtained results are reported in the follo-

wing Table 3.

TABLE 3 - Determination of the absolute and relative therapeutic indexes of the complex piroxicam/ β -cyclodextrin in comparison with piroxicam, expressed as the UD_0/ED_{30} ratio

Compound	Antiinflammatory activity ED_{30} (mg/kg)	Gastrolesive activity UD_0 (mg/kg)	Absolute therapeutic index	Relative therapeutic index
Complex piroxicam/ β -cyclodextrin	1.2	1.4	1.17	2.65
Piroxicam	2.5	1.1	0.44	1

From the examination of the results, it can be inferred that, in comparison with piroxicam alone, the complex piroxicam/ β -cyclodextrin shows a marked increase of activity, together with an improved gastric tolerability.

The ratio between these two values ie., the therapeutic index, proves to be particularly advantageous for the complex, being 2.65 times higher than that of the active ingredient as such, conventionally equal to 1.

Bioavailability and pharmacokinetic

For these investigations, male New Zealand White rabbits, weighing 2.5-3.0 kg were employed. The animals were kept at constant temperature and fastened for the 17 hours preceeding the experiments.

Water was given ad libitum.

- 10 -

The oral administration of the compounds to be tested was performed by oesophageal gavage, as a suspension in carboxymethylcellulose (CMC); the compounds were administered at a dosage corresponding to 10 mg/kg of active ingredient, at the constant volume of 10 ml/kg.

The determination of the plasma levels of the active principle, at the different times since the administration, was carried out by High Pressure Liquid Chromatography (HPLC). The obtained results are reported in Table 4.

The complex piroxicam/ β -cyclodextrin is able to induce high plasma levels of active ingredient, significantly higher than those observed after the administration of said active ingredient as such, even at 15, 30 and 60 minutes after its administration: it derives, therefore, that the AUC (Area Under (the) Curve plasma levels/times) of the complex piroxicam/ β -cyclodextrin, which refers to the first 2 hours after the treatment and is equal to $29.59 \pm 3.38 \text{ mcgml}^{-1} \cdot \text{h}$ ($\bar{X} \pm \text{S.E.}$), is significantly greater - 55% wider - than that of the active ingredient as such.

Moreover, the maximum concentration peak appears very soon (in the first 30 minutes since the beginning of the treatment), and is considerably higher than that obtained after administration of piroxicam as such.

On the other hand, the global bioavailability during the 24 hours remains more or less unchanged

- 11 -

ed: this is due to the fact that, in this animal species (rabbit), piroxicam itself displays indeed an almost complete bioavailability.

5 In another animal species i.e., the dog, in which the bioavailability patterns, particularly with reference to piroxicam, are somewhat similar to those observed in men, the behavior of the complex piroxicam/ β -cyclodextrin proved to be considerably different.

10 Four Beagle dogs, weighing 8-10.5 kg, were employed as the test animals. The dogs were kept at constant temperature and fastened at least for 17 hours before the beginning of the experiment. Water was available ad libitum.

15 The two substances to be investigated were orally administered at a dosage corresponding to 10 mg/kg of active ingredient, according to a crossover scheme. The determination of the plasma concentrations of the active ingredient, at different time intervals since the administration, was carried out
20 by High Pressure Liquid Chromatography (HPLC).

The obtained results are reported in Table 5.

From the comparison of the plasma kinetics, it appears evident that, as far as the absorption is
25 concerned, the two substances differ both from the qualitative and the quantitative standpoint; in fact, the plasma levels of the complexed form are extremely high (about 80% of the maximal values), and appear almost immediately (15 minutes after
30 the administration); contemporaneously, the analy-

- 12 -

sis of the AUCs in the time interval 0-2 hr makes evident a significant difference ($p < 0.005$) in the two treatments. Also the differences of the plasma concentrations at almost all of the observation times and, consequently, the AUCs in the time interval 0-72 hr, are absolutely significant. In view of these results, it can be concluded that, in the dog, the formation of an inclusion complex between piroxicam and β -cyclodextrin is capable of inducing not only an accelerated absorption, but also a global increase in bioavailability (about 40%). It must be pointed out that an immediate onset of the therapeutically useful plasma levels is of primary importance for the analgesic action, which must be rapid and effective.




TABLE 4 : Plasma kinetics of piroxicam in the rabbit, after oral administration of equivalent dosages in active ingredient (10 mg/kg) of piroxicam and piroxicam/ β -cyclodextrin (1:2.5).

(*) Statistically significant difference (Student t-test for independent data) with respect to the corresponding values obtained after administration of piroxicam

- 13 -

Compounds	N° of animals	Plasma concentrations (μgml^{-1}) of piroxicam ($\bar{X} \pm \text{S.E.}$) at the different times (h) after the administration								AUC ($\mu\text{gml}^{-1} \cdot \text{h}$) (O-24 h)	AUC ($\mu\text{gml}^{-1} \cdot \text{h}$) (O-2 h)	C_{max} (μgml^{-1})	T_{max} (h)
		0.25	0.50	1	2	4	8	24					
Piroxicam	6	\bar{X} +S.E.	-	4.3	7.4	10.9	10.1	6.5	0.3	121.28	13.17	11.7	2.3
			-	0.9	1.1	1.8	2.2	0.9	0.1	18.22	2.00	1.9	
Complex piroxicam/ β -cyclodextrin	5	\bar{X} +S.E.	15.1 2.9	17.3 1.5	16.6 2.0	13.8 1.6	8.5 0.8	3.8 0.9	0.9 0.5	114.53 12.96	29.59 3.38	18.4 2.0	0.6
$P_{(*)}$			-	<0.001	<0.005	N.S.	N.S.	N.S.	N.S.	N.S.	<0.005	<0.05	-

TABLE 5 : Plasma kinetics of piroxicam in the dog, after oral administration of equivalent dosages in active ingredient (10 mg/kg) of piroxicam and piroxicam/ β -cyclodextrin (1:2.5).

(*) Statistically significant difference (Student t-test for paired data) with respect to the corresponding values obtained after administration of piroxicam

Compounds	N° of animals		Plasma concentrations (μgml^{-1}) of piroxicam ($\bar{X} \pm \text{S.E.}$) at the different times (h) after the administration										AUC (0-72 h) $\mu\text{gml}^{-1} \cdot \text{h}$	AUC (0-2 h) $\mu\text{gml}^{-1} \cdot \text{h}$	C_{max} μgml^{-1}	T_{max} h
			0.25	0.50	1	2	4	8	24	48	72					
Piroxicam	4	\bar{X} $\pm \text{S.E.}$	1.0 0.4	2.8 1.0	12.7 2.6	19.4 0.6	18.9 0.2	14.2 0.3	11.5 0.7	9.2 0.4	3.0 0.3	723.64 20.33	20.44 2.18	20.0 0.2	1.8 -	
Complex piroxicam/ β -cyclodextrin	4	\bar{X} $\pm \text{S.E.}$	26.2 3.4	30.7 3.7	34.8 3.5	34.8 2.3	28.7 3.2	28.6 2.9	18.5 2.2	11.0 1.2	5.5 1.1	1167.53 97.45	61.53 5.43	35.7 2.9	1.5 -	
P (*)			<0.005	<0.01	<0.005	<0.005	N.S.	<0.025	N.S.	N.S.	<0.05	<0.025	<0.005	<0.025	-	

- 15 -

Kinetic of the analgesic activity

The kinetic of the oral analgesic activity of the complex piroxicam/ β -cyclodextrin in comparison with piroxicam was investigated by means of the phenylquinone induced writhing test, by evaluating the degree of protection displayed by the tested substances against a characteristic syndrome (writhing), induced upon intraperitoneal injection of 10 ml per kg of body weight of an aqueous solution of phenylquinone (0.02% in 5% aqueous ethanol). The employed experimental model is a slight modification of that described by Siegmund, J. Pharm. Exptl. Ther., 119, 184, 1957.

Female NMRI mice, housed under standard conditions, fastened for 18 hours, were employed as the test animals. Water was available ad libitum.

The compounds under study were orally administered by oesophageal gavage, suspended in an aqueous solution containing 0.5% of carboxymethylcellulose, at a concentration corresponding to 0.5 mg/kg of active substance (piroxicam).

The obtained results again confirm the noteworthy increase of the absorption rate of piroxicam, when complexed by inclusion into the β -cyclodextrin, in comparison with the active principle as such, following the oral administration. In fact, even 5 minutes after the administration, it was observed the 99% of the maximum evidenced inhibition for the complex piroxicam/ β -cyclodextrin, whereas that observed for piroxicam as such at the

- 16 -

same time was 78%.

The activity peak which, in the case of piroxicam/
B-cyclodextrin, is just that monitored after 5 mi-
nutes, appears only after 20 minutes in the case of
5 piroxicam as such.

All of these properties, namely the improved bio-
availability, the increase in activity as well as
its rapid onset, and the improved tolerability be-
stow on the compound of the invention a particular
10 therapeutic interest.

The present invention also refers to pharmaceuti-
cal compositions containing, as the active ingre-
dient, piroxicam complexed by inclusion into cyclo-
dextrins in the above defined ratios, in admixture
15 with pharmaceutically acceptable excipients.

The compositions can be administered by oral or
rectal route, respectively in the form of capsules,
tablets, bags, syrups, solutions and the like, or
suppositories.

20 In the preparation of pharmaceutical formula-
tions in dosage unit form suitable for the oral ad-
ministration, the active ingredient can be admixed
with a solid pulverized excipient such as, for in-
stance, lactose, saccharose, sorbitol, mannitol, po-
25 tato-corn, or maize starch or amylopectin, a cellu-
lose or gelatin derivative, and may also contain lu-
bricants, e.g. talc, magnesium or calcium stearate,
polyethyleneglycol or silica.

The tablets can be coated in different ways, ac-
30 cording to methods well known from the pharmaceuti-

- 17 -

cal practice. Hard gelatin capsules may contain granulates of the active ingredient in admixture with solid pulverized excipients such as, for instance, lactose, saccharose, sorbitol, mannitol, starches (as above indicated), cellulose or gelatin derivatives, and may also contain stearic acid, or magnesium stearate or talc.

Unit dosage forms for the rectal administration are generally represented by suppositories, and contain the active ingredient in admixture with a neutral fatty base (for instance, glycerides of fatty acids), or with water soluble or autoemulsifiable excipients (e.g., mixtures of polyethylene-glycols). The unit dosage for the above illustrated formulations may vary from about 10 to about 50 mg of active ingredient, and is preferably given in a single administration on a daily basis.

Some representative, but not limitative, pharmaceutical formulations according to the invention are hereinbelow reported for illustrative purposes.

Tablets

Piroxicam/ β -cyclodextrin (1:2.5) mg 191.2
(corresponding to 20 mg of piroxicam)

Microcrystalline cellulose or starch mg 80
Sodium carboxymethylstarch mg 8
Lactose or calcium phosphate mg 108
Magnesium stearate mg 2.8

Effervescent tablets

Piroxicam/ β -cyclodextrin (1:2.5) mg 191.2
(corresponding to 20 mg of piroxicam)

- 18 -

	Glycine sodium carbonate	mg	500
	Citric acid	mg	500
	Sodium benzoate	mg	40
	Polyethyleneglycol 6000	mg	15
5	Monoammonium glycyrrhizinate	mg	30
	Mint flavor	mg	5
	Saccharose	mg	718.8
	<u>Bags</u>		
10	Piroxicam/ β -cyclodextrin (1:2.5) (corresponding to 20 mg of piroxicam)	mg	191.2
	Silica gel	mg	10
	Sodium saccharine	mg	10
	Monoammonium glycyrrhizinate	mg	30
15	Mint flavor	mg	5
	Saccharose (mannitol, sorbitol, xylitol, fructose or mixture thereof)	mg	4753.8
	<u>Suppositories</u>		
20	Piroxicam/ β -cyclodextrin (1:2.5) (corresponding to 20 mg of piroxicam)	mg	191.2
	Semisynthetic solid glycerides	to	mg 1600.

- 19 -

CLAIMS. for the contracting States:

BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Compounds obtained by complexation of piroxicam with α , β - or γ -type cyclodextrins, in ratios
5 comprised between 1:1 and 1:10 of piroxicam and cyclodextrins respectively.
2. Compounds as defined in claim 1, wherein the piroxicam/cyclodextrin ratio is 1:2.5.
3. Compounds as defined in claim 1, wherein the
10 cyclodextrins are of β -type.
4. A process for preparing the compounds as defined in each of claims 1 to 3, characterized in that piroxicam and the cyclodextrins are reacted in an aqueous solution, from which the complex is recovered by crystallization.
15
5. A process for preparing the compounds as defined in each of claims 1 to 3, characterized in that a solution of piroxicam in an organic medium and an aqueous solution of β -cyclodextrin are reacted under stirring, and the obtained complex is subsequently separated by crystallization.
20
6. A process for preparing the compounds as defined in each of claims 1 to 3, characterized in that the two components are reacted under stirring in a hot aqueous solution of ammonium hydroxide.
25
7. A process as defined in claim 6, characterized in that the complex is isolated by evaporation of the solvent and subsequent drying up.
8. A process as defined in claim 6, characterized
30 in that the complex is recovered by freeze-drying

- 20 -

the solution.

9. A process as defined in claim 6, characterized in that the complex is recovered by atomization of the solution in air stream.

- 19 -

CLAIMS: AT

1. A process for preparing complexes of piroxicam with α , β or γ -type cyclodextrins in ratios comprised between 1:1 and 1:10 respectively, characterized in that piroxicam and the cyclodextrins are reacted in an aqueous solution, from which the complex is recovered by crystallization.
2. A process for preparing complexes of piroxicam with α , β or γ -type cyclodextrins in ratios comprised between 1:1 and 1:10 respectively, characterized in that a solution of piroxicam in an organic medium and an aqueous solution of β -cyclodextrin are reacted under stirring, and the obtained complex is subsequently separated by crystallization.
3. A process for preparing complexes of piroxicam with α , β or γ -type cyclodextrins in ratios comprised between 1:1 and 1:10 respectively, characterized in that the two components are reacted under stirring in a hot aqueous solution of ammonium hydroxide.
4. A process as defined in claim 3, characterized in that the complex is isolated by evaporation of the solvent and subsequent drying up.
5. A process as defined in claim 3, characterized in that the complex is recovered by freeze-drying the solution.
6. A process as defined in claim 3, characterized in that the complex is recovered by atomization of the solution in air stream.

0153998




FIG. 1



This Page Blank (uspto)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 153 998
A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 84113923.1

(51) Int. Cl.⁴: C 08 B 37/16

(22) Date of filing: 17.11.84

(30) Priority: 22.02.84 IT 1973584

(43) Date of publication of application:
11.09.85 Bulletin 85/37

(88) Date of deferred publication of search report: 14.01.87

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE(71) Applicant: CHIESI FARMACEUTICI S.p.A.
Via Palermo, 26/A
I-43100 Parma(IT)(72) Inventor: Chiesi, Paolo
Via Palermo, 26/A
Parma(IT)(72) Inventor: Servadio, Vittorino
Via Palermo, 26/A
Parma(IT)(74) Representative: Bianchetti, Giuseppe
Studio Consulenza Brevettuale Via Rossini, 8
I-20122 Milan(IT)

(54) New compounds having antiinflammatory activity, obtained by complexation with beta-cyclodextrin, and pharmaceutical compositions containing them.

(57) New inclusion compounds of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide with α , β or γ cyclodextrins, obtained by reaction of said cyclodextrins and said 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide in aqueous or water/organic solutions are described. The ratio between 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-1,1-dioxide and the cyclodextrins is comprised between 1:10 and 1:1, preferably, it is about 1:2.5.

The compounds of the invention possess high anti-inflammatory and analgesic activities, together with a considerably reduced gastrolesive action.



European Patent
Office

EUROPEAN SEARCH REPORT

01 53998

Application number

EP 84 11 3923

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
A	FR-A-2 530 143 (CIBA-GEIGY)		C 08 B 37/16
A	--- CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 23, no. 1, 1975, pages 188-195; M. OTAGIRI et al.: "Inclusion complexes of beta-cyclodextrin with tranquilizing drugs phenothiazines in aqueous solution"		
A	--- EP-A-0 082 921 (KAKENYAKU KAKO CO. LTD.) -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 08 B A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 30-10-1986	Examiner LENSEN H.W.M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)